EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path

EyePoint Pharmaceuticals reported that its Duravyu Phase III trial for wet AMD missed the primary endpoint of visual acuity non-inferiority to aflibercept, relying on a second Phase III trial, LUCIA, for FDA approval. Despite this, Duravyu showed significant treatment burden reduction and safety benefits, with LUCIA results expected in Q4 2026 guiding the regulatory path.

This Wire brief sits within Fusion42's coverage of Medtech.